Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label emicizumab Q2W vs Q4W in pediatric hemophilia A without inhibitors
jRCT2080223654Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2017
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Efficacy of emicizumab Q2W and Q4W, Safety of emicizumab Q2W and Q4W and 1 more. Started Sep 2017; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080223654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223654.